Baseline characteristics of patients
| All patients | Patients with swollen joints at baseline | |||||||
|---|---|---|---|---|---|---|---|---|
| Overall (n=440) | No co-medication (n=170) | MTX co-medication (n=270) | p Value | Overall (n=330) | No co-medication (n=111) | MTX co-medication (n=219) | p Value | |
| Age (years) | 46.5 (11.6) | 47.0 (11.4) | 46.1 (11.7) | 0.46 | 46.9 (11.8) | 48.4 (10.8) | 46.1 (12.3) | 0.11 |
| Women (%) | 46.4 | 47.6 | 45.6 | 0.70 | 47.3 | 47.7 | 47.0 | 0.91 |
| Disease duration (years)* | 5.2 (1.5–12.5) | 5.1 (1.1–11.7) | 5.5 (1.6–12.7) | 0.44 | 6.1 (2.0–13.2) | 5.8 (2.6–14.3) | 6.1 (1.8–13.2) | 0.73 |
| Current smoker (%) | 30.3 | 31.0 | 29.9 | 0.83 | 31.2 | 33.9 | 29.9 | 0.45 |
| Number of prev. DMARDs | 1.49 (1.09) | 1.49 (1.20) | 1.48 (1.02) | 0.30 | 1.66 (1.08) | 1.86 (1.12) | 1.56 (1.04) | 0.02 |
| Swollen joints* | 3 (1–6) | 2 (0–5) | 3 (1–7) | 0.004 | 4 (2–7) | 4 (2–7) | 4 (2–7) | 0.68 |
| ≥1 swollen (%) | 77.6 | 68.5 | 83.3 | 0.001 | NA | NA | NA | NA |
| CRP mg/litre* | 9 (5–20) | 7 (5–22) | 9 (5–20) | 0.44 | 10 (5–25) | 10 (5–26) | 10 (5–22) | 0.73 |
| Physician global (0–100) | 37.4 (17.9) | 39.6 (19.2) | 36.0 (16.9) | 0.04 | 39.3 (17.5) | 42.6 (19.5) | 37.6 (16.2) | 0.02 |
| Patient global (0–100) | 54.6 (23.7) | 56.5 (22.8) | 53.4 (22.5) | 0.17 | 55.5 (22.7) | 58.5 (22.3) | 54.0 (22.7) | 0.09 |
| MHAQ score (0–3) | 0.70 (0.46) | 0.72 (0.47) | 0.69 (0.46) | 0.41 | 0.74 (0.46) | 0.79 (0.44) | 0.71 (0.46) | 0.16 |
| SF-6D score (0–1) | 0.59 (0.12) | 0.57 (0.12) | 0.60 (0.12) | 0.01 | 0.59 (0.12) | 0.56 (0.10) | 0.60 (0.12) | 0.01 |
| Modified DAPSA | NA | NA | NA | NA | 46.0 (38.6) | 47.5 (34.3) | 45.2 (40.7) | 0.63 |
| DAS28 | NA | NA | NA | NA | 4.57 (1.20) | 4.74 (1.31) | 4.49 (1.12) | 0.09 |
Mean (SD) values for continuous variables if not stated otherwise.
*Median (IQR).
DAPSA, Disease Activity Index for Psoriatic Arthritis; DAS28, Disease Activity Score-28; DMARD, disease-modifying antirheumatic drug; MHAQ, Modified Health Assessment Questionnaire; MTX, methotrexate; SF-6D, Short Form 6 Dimensions.